Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 3
1995 1
1996 2
1997 2
1998 6
1999 4
2000 5
2001 1
2002 2
2003 4
2004 2
2005 3
2006 7
2007 9
2008 4
2009 2
2010 7
2011 9
2012 3
2013 5
2014 3
2015 3
2016 7
2017 6
2018 3
2019 3
2020 4
2021 9
2022 3
2023 3
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

109 results

Results by year

Filters applied: . Clear all
Page 1
Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma.
Sonneveld P, Zweegman S, Cavo M, Nasserinejad K, Broijl A, Troia R, Pour L, Croockewit S, Corradini P, Patriarca F, Wu K, Droogendijk J, Bos G, Hajek R, Teresa Petrucci M, Ypma P, Zojer N, Minnema MC, Boccadoro M. Sonneveld P, et al. Among authors: zojer n. Hemasphere. 2022 Sep 30;6(10):e786. doi: 10.1097/HS9.0000000000000786. eCollection 2022 Oct. Hemasphere. 2022. PMID: 36204691 Free PMC article.
Hematological emergencies.
Zojer N, Ludwig H. Zojer N, et al. Ann Oncol. 2007 Jan;18 Suppl 1:i45-i48. doi: 10.1093/annonc/mdl450. Ann Oncol. 2007. PMID: 17311822 Free article. Review. No abstract available.
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders.
Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, Eichner R, Erl M, Esterbauer H, Exner R, Felsleitner-Hauer V, Forte M, Gaiger A, Geissler K, Greinix HT, Gstöttner W, Hacker M, Hartmann BL, Hauswirth AW, Heinemann T, Heintel D, Hoda MA, Hopfinger G, Jaeger U, Kazianka L, Kenner L, Kiesewetter B, Krall N, Krajnik G, Kubicek S, Le T, Lubowitzki S, Mayerhoefer ME, Menschel E, Merkel O, Miura K, Müllauer L, Neumeister P, Noesslinger T, Ocko K, Öhler L, Panny M, Pichler A, Porpaczy E, Prager GW, Raderer M, Ristl R, Ruckser R, Salamon J, Schiefer AI, Schmolke AS, Schwarzinger I, Selzer E, Sillaber C, Skrabs C, Sperr WR, Srndic I, Thalhammer R, Valent P, van der Kouwe E, Vanura K, Vogt S, Waldstein C, Wolf D, Zielinski CC, Zojer N, Simonitsch-Klupp I, Superti-Furga G, Snijder B, Staber PB. Kornauth C, et al. Among authors: zojer n. Cancer Discov. 2022 Feb;12(2):372-387. doi: 10.1158/2159-8290.CD-21-0538. Epub 2021 Oct 11. Cancer Discov. 2022. PMID: 34635570 Free PMC article.
[Anemias].
Zojer N, Ludwig H. Zojer N, et al. Wien Klin Wochenschr. 2006 Sep;118(17-18 Suppl 2):69-83; quiz 84. doi: 10.1007/s11812-006-0008-3. Wien Klin Wochenschr. 2006. PMID: 17598316 German. No abstract available.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
SLiM CRAB criteria revisited: temporal trends in prognosis of patients with smoldering multiple myeloma who meet the definition of 'biomarker-defined early multiple myeloma'-a systematic review with meta-analysis.
Ludwig H, Kainz S, Schreder M, Zojer N, Hinke A. Ludwig H, et al. Among authors: zojer n. EClinicalMedicine. 2023 Mar 20;58:101910. doi: 10.1016/j.eclinm.2023.101910. eCollection 2023 Apr. EClinicalMedicine. 2023. PMID: 36969337 Free PMC article.
Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma.
Ludwig H, Melchardt T, Sormann S, Schreder M, Andel J, Hartmann B, Tinchon C, Zojer N, Gunsilius E, Podar K, Egle A, Willenbacher W, Wöll E, Ruckser R, Bozic B, Krauth MT, Petzer A, Schmitt C, Machherndl-Spandl S, Agis H, Fillitz M, Wang SY, Zabernigg A, Knop S, Paiva B, Greil R. Ludwig H, et al. Among authors: zojer n. Am J Hematol. 2024 May;99(5):1008-1011. doi: 10.1002/ajh.27280. Epub 2024 Feb 29. Am J Hematol. 2024. PMID: 38425185 Clinical Trial.
Supportive care.
Ludwig H, Zojer N. Ludwig H, et al. Among authors: zojer n. Ann Oncol. 2007 Jan;18 Suppl 1:i37-i44. doi: 10.1093/annonc/mdl449. Ann Oncol. 2007. PMID: 17311821 Free article. Review. No abstract available.
Supportive therapy in multiple myeloma.
Ludwig H, Zojer N. Ludwig H, et al. Among authors: zojer n. Recent Results Cancer Res. 2011;183:307-33. doi: 10.1007/978-3-540-85772-3_15. Recent Results Cancer Res. 2011. PMID: 21509692 Review.
109 results